Iradimed Co Stock Price Prediction
| IRMD Stock | USD 53.39 0.16 0.30% |
Oversold Vs Overbought
70
Oversold | Overbought |
Quarterly Earnings Growth (0) | EPS Estimate Next Quarter 0.39 | EPS Estimate Current Year 1.655 | EPS Estimate Next Year 1.75 | Wall Street Target Price 60 |
Using Iradimed hype-based prediction, you can estimate the value of Iradimed Co from the perspective of Iradimed response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Iradimed to buy its stock at a price that has no basis in reality. In that case, they are not buying Iradimed because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Iradimed after-hype prediction price | USD 52.21 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Iradimed |
Iradimed After-Hype Price Prediction Density Analysis
As far as predicting the price of Iradimed at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Iradimed or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Iradimed, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Iradimed Estimiated After-Hype Price Volatility
In the context of predicting Iradimed's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Iradimed's historical news coverage. Iradimed's after-hype downside and upside margins for the prediction period are 50.03 and 54.39, respectively. We have considered Iradimed's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Iradimed is very steady at this time. Analysis and calculation of next after-hype price of Iradimed is based on 3 months time horizon.
Iradimed Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Iradimed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iradimed backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Iradimed, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.25 | 2.18 | 1.18 | 0.08 | 9 Events / Month | 11 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
53.39 | 52.21 | 2.21 |
|
Iradimed Hype Timeline
Iradimed is currently traded for 53.39. The entity has historical hype elasticity of -1.18, and average elasticity to hype of competition of -0.08. Iradimed is expected to decline in value after the next headline, with the price expected to drop to 52.21. The average volatility of media hype impact on the company price is about 46.28%. The price decrease on the next news is expected to be -2.21%, whereas the daily expected return is currently at 0.25%. The volatility of related hype on Iradimed is about 712.02%, with the expected price after the next announcement by competition of 53.31. About 37.0% of the company shares are held by company insiders. The company last dividend was issued on the 15th of November 2024. Given the investment horizon of 90 days the next expected press release will be in about 9 days. Check out Iradimed Basic Forecasting Models to cross-verify your projections.Iradimed Related Hype Analysis
Having access to credible news sources related to Iradimed's direct competition is more important than ever and may enhance your ability to predict Iradimed's future price movements. Getting to know how Iradimed's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Iradimed may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| LUNG | Pulmonx Corp | (0.05) | 7 per month | 4.10 | (0.01) | 9.00 | (6.89) | 20.52 | |
| OFIX | Orthofix Medical | 0.12 | 9 per month | 2.03 | 0.04 | 3.90 | (3.85) | 12.11 | |
| NPCE | Neuropace | 0.13 | 10 per month | 3.00 | 0.09 | 9.73 | (6.19) | 35.38 | |
| ITGR | Integer Holdings Corp | (2.86) | 9 per month | 1.44 | 0.03 | 2.48 | (2.16) | 7.64 | |
| GKOS | Glaukos Corp | 2.86 | 8 per month | 1.66 | 0.02 | 3.30 | (2.86) | 13.23 | |
| HSKA | Heska | 0.15 | 8 per month | 0.00 | 0.17 | 3.63 | (0.71) | 21.36 | |
| CNMD | CONMED | (0.47) | 10 per month | 2.27 | 0.02 | 4.57 | (3.83) | 11.47 | |
| OSA | ProSomnus, Common Stock | 0 | 1 per month | 13.81 | 0.13 | 51.22 | (20.31) | 168.97 | |
| LIVN | LivaNova PLC | (1.87) | 9 per month | 1.42 | 0.03 | 3.73 | (2.55) | 8.68 | |
| ELMD | Electromed | 0.34 | 8 per month | 2.15 | 0.28 | 6.65 | (4.47) | 13.47 | |
| KIDS | Orthopediatrics Corp | (2.28) | 10 per month | 0.00 | (0.08) | 5.04 | (5.08) | 19.39 | |
| SRDX | SurModics | (0.09) | 6 per month | 0.00 | (0.23) | 1.26 | (1.01) | 3.22 | |
| SGHT | Sight Sciences | (0.43) | 9 per month | 0.00 | (0.18) | 6.96 | (7.84) | 18.22 | |
| ANIK | Anika Therapeutics | 0.16 | 9 per month | 0.00 | (0.14) | 3.23 | (2.96) | 34.28 |
Iradimed Additional Predictive Modules
Most predictive techniques to examine Iradimed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Iradimed using various technical indicators. When you analyze Iradimed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Iradimed Predictive Indicators
The successful prediction of Iradimed stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Iradimed Co, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Iradimed based on analysis of Iradimed hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Iradimed's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Iradimed's related companies. | 2023 | 2024 (projected) | Dividend Yield | 0.0221 | 0.0316 | Price To Sales Ratio | 9.13 | 9.61 |
Story Coverage note for Iradimed
The number of cover stories for Iradimed depends on current market conditions and Iradimed's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Iradimed is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Iradimed's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Iradimed Short Properties
Iradimed's future price predictability will typically decrease when Iradimed's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Iradimed Co often depends not only on the future outlook of the potential Iradimed's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Iradimed's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.7 M | |
| Cash And Short Term Investments | 49.8 M |
Complementary Tools for Iradimed Stock analysis
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |